NOVOB (NOVOB) News
Follow NOVOB (NOVOB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 119 public stories across 27 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Novo Nordisk Expected to Raise Full-Year Guidance on Strong Q3 Results
J.P. Morgan analysts anticipate Novo Nordisk will report strong third-quarter results and subsequently raise its full-year guidance. The bank forecasts adjusted sales of 76 billion Danish kroner, exceeding Bloomberg cons
EQUITY | Oct 05, 2026, 08:04 AM UTC
M
Regeneron drug halves muscle loss with Novo's semaglutide in trial
An experimental weight-loss drug developed by Regeneron (REGN), when combined with Novo Nordisk's (NOVO_B) semaglutide, reduced muscle mass loss by 50% compared to semaglutide alone in a study of obese patients, accordin
EQUITY | Sep 30, 2026, 10:30 PM UTC
H
Lilly's experimental drug shows superiority over Zepbound in weight-loss trial
Eli Lilly announced that its experimental combination weight-loss drug demonstrated superior performance compared to its own blockbuster drug, Zepbound, in a head-to-head trial. This intensifies competition in the obesit
EQUITY | Sep 30, 2026, 05:32 PM UTC
M
Lilly's experimental drug outperforms Zepbound in weight-loss trial
Eli Lilly's experimental combination weight-loss drug showed superior results compared to its own blockbuster Zepbound in a head-to-head trial, increasing competition with Novo Nordisk for obesity therapies.
EQUITY | Sep 30, 2026, 02:16 PM UTC
L
Novo Nordisk (NOVO_B) Reports CagriSema Cut Weight 22.4% in 52 Weeks
Novo Nordisk reported that investigational CagriSema reduced body weight by 22.4% vs placebo at 52 weeks in an fMRI study and showed ectopic fat reductions in a diabetes sub-study, with additional bone marker findings in
NEWS | Sep 30, 2026, 12:31 PM UTC
L
Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health — EASD 2026
Bagsværd, Denmark, 30 September 2026 — Novo Nordisk today announced new data on how CagriSema works inside both the brain and body, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 20
NEWS | Sep 30, 2026, 12:31 PM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Ro Announces Research Collaboration With Novo On Wegovy Pill
Ro
NEWS | Sep 30, 2026, 09:50 AM UTC
L
Ro And Novo Announce Research Collaboration To Generate First-Of-Its-Kind Real-World Evidence On The Wegovy® Pill
Rubicon Organics Inc TSXV:ROMJ
NEWS | Sep 30, 2026, 09:46 AM UTC
L
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
By Patrick WingrovePatients who switched from weight-loss injections to Novo Nordisk's OMXCOP:NOVO_B daily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish
NEWS | Sep 30, 2026, 09:45 AM UTC
L
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy
Eli Lilly (LLY, Financials) says higher doses of Zepbound may have widened its weight-loss advantage over Novo Nordisk's Wegovy.A new indirect analysis found that patients receiving Zepbound 15 mg and 10 mg had 4.5 perce
NEWS | Sep 29, 2026, 06:18 PM UTC
L
Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
More than 630,000 U.S. adults with type 2 diabetes were included in a real-world analysis examining treatment changes involving semaglutide and tirzepatide, Novo Nordisk (NVO) said Tuesday.The analysis covered patients r
NEWS | Sep 29, 2026, 03:58 PM UTC
L
Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events
Novo Nordisk A/S OMXCOP:NOVO_B
NEWS | Sep 29, 2026, 02:13 PM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
L
Novo Nordisk to pay up to $2.6bn for rights to Hengrui Pharma weight-loss drug
The license agreement with China’s Hengrui is for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor NASDAQ:GIPR dual agonist, with potential for once-weekly o
GEOPOLITICS | Sep 29, 2026, 12:00 PM UTC
L
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
Novo Nordisk OMXCOP:NOVO_B said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compared to t
NEWS | Sep 29, 2026, 11:06 AM UTC
L
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Eli Lilly NYSE:LLY said its oral obesity drug, Foundayo, offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's OMXCOP:NOVO_B Ozempic pill in adults with type 2 diabetes, citing da
NEWS | Sep 29, 2026, 10:46 AM UTC
L
Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro
Novo Nordisk OMXCOP:NOVO_B said on Tuesday a real-world study found that adults with type 2 diabetes who escalated their dose of diabetes drug Ozempic to 2 milligrams (mg) from 1 mg had a lower risk of major cardiovascul
NEWS | Sep 29, 2026, 10:29 AM UTC
L
LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding
Eli Lilly (LLY) was in the spotlight on Tuesday after a new analysis suggested that its once-daily Foundayo pill could deliver greater weight loss and reductions in blood sugar levels than Novo’s (NVO) higher-dose oral s
EQUITY | Sep 29, 2026, 10:21 AM UTC
L
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui
Novo Nordisk OMXCOP:NOVO_B will pay $300 million upfront to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental GLP-1 pill, the Chinese drugmaker said on Tuesday.The deal gains Novo a further pot
GEOPOLITICS | Sep 29, 2026, 05:53 AM UTC
L
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
By Fabiana Negrin OchoaNovo Nordisk has signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.The Danish drugmaker will pay China-based Hengrui $300
GEOPOLITICS | Sep 29, 2026, 05:00 AM UTC
L
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Jiangsu Hengrui Pharmaceuticals SSE:600276, China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S OMXCOP:NOVO_B in a deal wort
GEOPOLITICS | Sep 29, 2026, 04:44 AM UTC
L
Novo And Hengrui Pharma Enter Exclusive License Agreement For HRS-1596
Novo Nordisk A/S OMXCOP:NOVO_B
NEWS | Sep 29, 2026, 04:44 AM UTC
L
Novo Nordisk (NOVO_B) Licenses HRS-1596 In Deal Worth Up To $2.6B
Novo Nordisk entered an exclusive license with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP agonist, including $300M upfront and up to $2.6B in milestones. Rights cover all markets except mainl
GEOPOLITICS | Sep 29, 2026, 04:38 AM UTC
L
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Bagsværd, Denmark, 29 September 2026 — Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (G
NEWS | Sep 29, 2026, 04:38 AM UTC
L
Anthropic rolls out second Claude 5.5 model as it builds toward IPO
Anthropic on Monday released Claude Sonnet 5.5, the second model in its Claude 5.5 family, as the AI lab expands its product lineup ahead of a planned IPO.Here are some more details
EQUITY | Sep 28, 2026, 06:00 PM UTC
L
Novo Nordisk A/S (NOVO_B) Updates DKK 15B Buyback Progress
Novo Nordisk confirms its 12—month buyback of up to DKK 15B begun 4 Feb 2026. As of 25 Sep 2026, it has repurchased 35,379,179 B shares for DKK 9.94B at an average DKK 280.95 and holds 49,419,876 B shares (1.1%) as treas
EQUITY | Sep 28, 2026, 01:51 PM UTC
L
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 28 September 2026 — On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MA
NEWS | Sep 28, 2026, 01:51 PM UTC
L
Weekly Recap: Pipeline and oral GLP-1 scale-up and CagriSema FDA timeline
Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) is executing a cost—cutting, multi—blockbuster push—10x oral GLP—1 capacity, CagriSema launch and Wegovy expansion—while investors fret over semaglutide patent cliff
REGULATION | Sep 28, 2026, 05:01 AM UTC
L
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Biotech investors face a crowded final week of September as Eli Lilly (LLY) and Novo Nordisk (NVO) bring their latest obesity and diabetes research to a major medical meeting in Milan, while uniQure (QURE) and Scynexis (
NEWS | Sep 28, 2026, 03:31 AM UTC
L
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Biotech dealmaking this week was lighter on blockbuster takeovers than earlier in 2026, but the tape was busy: Eli Lilly, Novo Nordisk, Novartis and AbbVie used licenses and research pacts to buy access to platforms rath
NEWS | Sep 26, 2026, 01:03 AM UTC
L
Mylan asks US court to clear Wegovy generic from Novo patent claims
By Blake BrittainGeneric drugmaker Viatris NASDAQ:VTRS has sued Danish pharmaceutical giant Novo Nordisk OMXCOP:NOVO_B in Delaware federal court, seeking a ruling that its proposed generic of Novo's blockbuster GLP-1 dru
NEWS | Sep 25, 2026, 07:19 PM UTC
L
Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem
Novo Nordisk (NVO, Financials), has agreed to pay up to 1.165 billion ($1.3 billion) for access to drug-delivery technology that could help the company develop obesity and diabetes treatments requiring fewer injections.T
NEWS | Sep 25, 2026, 02:08 PM UTC
L
Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech
Novo Nordisk NYSE:NVO shares were unchanged in Copenhagen after the company signed a global exclusive license and collaboration deal worth up to 1.165 billion ($1.3 billion) with Nanexa, a Swedish drug delivery company.
EQUITY | Sep 25, 2026, 01:58 PM UTC
L
Shares in Nanexa soar on €1bn Novo Nordisk deal
The Novo Nordisk, the manufacturer of Ozempic and Wegovy, has signed an exclusive licence to use Nanexa’s proprietary drug delivery technology PharmaShell platform for certain therapeutic peptide drugs for various indica
EQUITY | Sep 25, 2026, 09:40 AM UTC
L
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
By Dominic ChoppingNovo Nordisk agreed to pay up to $1.3 billion to license and develop Swedish pharmaceutical company Nanexa's drug delivery technology in a deal that could cut the frequency that patients need to inject
NEWS | Sep 25, 2026, 08:19 AM UTC
L
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Shares in Swedish drug-delivery company Nanexa OMXSTO:NANEXA more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk OMXCOP:NOVO_B worth up to about €1.17 billion (
EQUITY | Sep 25, 2026, 07:55 AM UTC
L
Nanexa And Novo Enter Global License, Collaboration Deal
Nanexa AB OMXSTO:NANEXA:Source text for Workspace:Further company coverage
NEWS | Sep 25, 2026, 06:57 AM UTC
L
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
The US Food and Drug Administration has approved Eli Lilly's NYSE:LLY once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients an alternative to daily long-act
REGULATION | Sep 24, 2026, 11:26 AM UTC
L
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
Shares of Novo Nordisk (NVO) fell again on Wednesday as investors kept looking for nearer-term answers on pricing and competition to its obesity and diabetes drugs, even after CEO Mike Doustdar said the company is open t
EQUITY | Sep 23, 2026, 08:37 PM UTC
L
Novo's Oral Wegovy Just Revealed a Surprising Weight-Loss Signal
Novo Nordisk (NVO, Financials) is getting another data point for its oral Wegovy program, with real-world study suggesting that those who recently gained weight can get higher weight-loss effects from the medication.The
NEWS | Sep 23, 2026, 07:31 PM UTC
L
Huge News For Novo Nordisk Fans
Novo Nordisk NYSE:NVO is considering hair loss as one possible area for future expansion as it looks beyond its core obesity and diabetes franchises, with the idea emerging alongside a broader strategy reset.Chief Scient
NEWS | Sep 23, 2026, 03:11 PM UTC
L
Novo Nordisk’s obesity feast lacks a second course
By Aimee DonnellanThe $174 bln weight loss pioneer plans to expand in new treatments. Yet a promised extra $23 bln of revenue by 2035 will barely offset the loss of sales as its core Wegovy franchise comes off patent. An
NEWS | Sep 23, 2026, 10:34 AM UTC
H
Before the bell: Europe higher as oil stays below $100
BEFORE THE BELL: EUROPE HIGHER AS OIL STAYS BELOW $100Europe was set for a positive start on Wednesday as global stocks and bonds found support from a slide in oil prices after US signals of diplomatic progress towards e
COMMODITIES | Sep 23, 2026, 06:51 AM UTC
L
Denmark's central bank sees 4% GDP growth in 2026, boosted by pharmaceutical industry
Denmark's central bank raised its GDP forecast for this year to 4% growth and its 2027 forecast to 2.3% growth from a previous prediction of 1.8% for both."Growth has been driven primarily by an extraordinary increase in
CENTRAL_BANK | Sep 23, 2026, 06:43 AM UTC
L
Novo Nordisk open to direct New York listing, CEO Doustdar tells FT
Novo Nordisk OMXCOP:NOVO_B is open to considering a direct New York Stock Exchange listing, replacing the American depositary receipts through which US investors currently trade its shares, CEO Mike Doustdar told the Fin
EQUITY | Sep 23, 2026, 05:06 AM UTC
L
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT
Novo Nordisk OMXCOP:NOVO_B is open to the idea of upgrading its New York listing as part of efforts to raise the Danish weight-loss drugmaker's profile in the country, its chief executive told Financial Times in an inter
NEWS | Sep 23, 2026, 04:12 AM UTC
L
Ozempic-Maker Novo Open To Upgrading Us Listing - Ft
Ozempic-Maker Novo Open To Upgrading Us Listing - Ft
NEWS | Sep 23, 2026, 04:06 AM UTC
M
Novo CEO says weight-loss pills could capture 50% by 2030
Novo Nordisk CEO Mike Doustdar tells Reuters that weight-loss pills could take up to half of the global obesity-drug market by 2030 as the company prepares for a shift away from weekly injections.
EQUITY | Sep 22, 2026, 03:13 PM UTC
M
Novo Nordisk expands partnership with UNICEF, commits $18 million
EQUITY | Sep 22, 2026, 01:02 PM UTC
M
Roche obesity drug shows blood sugar control and 15.5% weight loss
Roche said its experimental dual-acting obesity drug improved blood sugar control and drove an average 15.5% body-weight loss in a mid-stage trial in overweight or obese patients with type 2 diabetes.
EQUITY | Sep 22, 2026, 11:22 AM UTC
M
Novo Nordisk shares fall 8% after investor day
Novo Nordisk’s shares fell about 8% after its investor day on Monday, with Jyske Bank saying the reaction may be harsh.
EQUITY | Sep 22, 2026, 06:16 AM UTC
M
VKTX, GPCR, ALT stocks jump after Novo Nordisk M&A signal
Novo Nordisk said it could pursue larger acquisitions while targeting more than five “multi-blockbuster” launches by 2030, lifting smaller obesity players: Viking Therapeutics gained nearly 4%, Structure Therapeutics ros
EQUITY | Sep 22, 2026, 05:29 AM UTC
M
Lilly rises after Novo reports CagriSema beats 5mg tirzepatide
Novo Nordisk said CagriSema beat tirzepatide’s 5-milligram dose in a late-stage diabetes study. Lilly shares still climbed about 1.2% to $1,166.74.
EQUITY | Sep 21, 2026, 07:11 PM UTC
M
Novo Nordisk says CagriSema outperformed Lilly’s Zepbound in Phase 3
Novo Nordisk said its CagriSema (cagrilintide plus semaglutide) at 1 mg each achieved greater weight loss than Eli Lilly’s Zepbound in a Phase 3 trial, reporting 12.4% weight loss.
EQUITY | Sep 21, 2026, 02:52 PM UTC
M
Novo Nordisk buys 34,174,179 B shares for DKK 9.63B
Novo Nordisk reaffirmed a plan to repurchase up to DKK 15B of B shares over 12 months from 4 Feb 2026. As of 18 Sep 2026, it bought 34,174,179 B shares for DKK 9.63B at an average price of DKK 281.79 and holds 48,214,876
EQUITY | Sep 21, 2026, 12:44 PM UTC
M
Novo Nordisk outlines plan for five multi-blockbusters by decade end
Novo Nordisk says it plans to launch at least five new “multi-blockbusters” by the end of the decade to drive growth and offset slowing sales, after shortening its brand name to Novo last week.
EQUITY | Sep 21, 2026, 12:29 PM UTC
M
Novo Nordisk shares slide after 2030 strategic ambitions
Novo Nordisk (NVO) shares fell about 5.96% in Copenhagen trading after the company used its London Capital Markets Day to outline 2030 strategic ambitions under new CEO Mike Doustdar.
EQUITY | Sep 21, 2026, 12:21 PM UTC
M
Novo Nordisk sets five-plus blockbuster targets by 2030; NVO slips
Novo Nordisk said it targets over five new blockbusters by 2030, but provided limited near-term catalysts, with investors citing competition concerns from Eli Lilly. U.S.-listed NVO shares were down 5% at the time of wri
EQUITY | Sep 21, 2026, 11:33 AM UTC
M
Novo Nordisk says CagriSema beat Lilly rival in diabetes trial
Novo Nordisk said CagriSema delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly’s rival drug.
EQUITY | Sep 21, 2026, 11:14 AM UTC